- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Mast Cell Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
- Interventions
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Fludarabine, Total-Body Irradiation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 522
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Myelofibrosis, Secondary Myelofibrosis
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Ruxolitinib, Ruxolitinib Phosphate, Sirolimus, Tacrolimus
- Procedure · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Syngeneic Bone Marrow Transplantation, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Covid19
- Interventions
- Standard of Care, SARS-CoV2-CTLS
- Other · Biological
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Valhalla, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoproliferative Disorders
- Interventions
- Cellular therapy product
- Biological
- Lead sponsor
- Leland Metheny
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Congenital Amegakaryocytic Thrombocytopenia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
- Interventions
- anti-thymocyte globulin, therapeutic allogeneic lymphocytes, fludarabine phosphate, thiotepa, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- San Francisco, California • Chapel Hill, North Carolina
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- MultiTAA-specific T cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Hurler Syndrome, Inherited Metabolic Disorder, Lysosomal Storage Disorder, Metachromatic Leukodystrophy, Inborn Errors of Metabolism
- Interventions
- rivogenlecleucel, rimiducid
- Biological · Drug
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 3 Months to 21 Years
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Palo Alto, California
- Conditions
- Hematologic Diseases
- Interventions
- Allogeneic Stem Cell Transplant, CliniMACS Prodigy System, T-allo10 cells addback
- Biological · Device · Drug
- Lead sponsor
- Porteus, Matthew, MD
- Other
- Eligibility
- 1 Month to 45 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
- Interventions
- Viral Specific VST Infusion
- Biological
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Days and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 4
- States / cities
- Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
- Biological · Drug · Radiation
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- AML/MDS, B-ALL, T-ALL, BPDCN
- Interventions
- CD123-CAR T, Cyclophosphamide, Fludarabine, Mesna, Rituximab
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Allogeneic Stem Cell Transplant, Viral Infection
- Interventions
- Viral Specific T-cells (VSTs)
- Biological
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Secondary Myelofibrosis, Small Intestine Cancer
- Interventions
- anti-thymocyte globulin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, methotrexate, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Duarte, California
- Conditions
- Hematologic Disorders
- Interventions
- Miltenyi CliniMACS® CD34 Reagent System
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Immune Tolerance
- Interventions
- Hematopoietic cell transplantation, Total lymphoid irradiation
- Biological · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Neuroblastoma
- Interventions
- Humanized anti-GD2 antibody, Chemotherapy, Cytokines, Natural killer cells, CliniMACS
- Biological · Drug · Other + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Myeloid Leukemia
- Interventions
- ALT-803
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cancer
- Interventions
- graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
- Biological · Genetic · Other + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 8
- States / cities
- Cleveland, Ohio
- Conditions
- Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
- Interventions
- T-cell replete PBPC allograft, Methotrexate, Cyclosporine, G-CSF
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hematologic Malignancies
- Interventions
- BPX-501, AP1903
- Biological · Drug
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma, Graft Versus Host Disease
- Interventions
- cyclosporine, cyclosporine and methotrexate
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more